All the Active Ingredient Drugs
PADCEV
Astellas
PADCEV
Antineoplastic. Enfortumab vedotin 20 mg, Enfortumab vedotin 30 mg. VIAL 1X 20/30 mg powder for IV inf.
1.25 mg/kg (up to max 125 mg for pts. ≥ 100 kg) admin as an IV inf. over 30 min. on Days 1, 8 and 15 of a 28-day cycle until dis. progr. or unacceptable tox.
Aults with locally adv. or metast. urothelial cancer (mUC) who:
• have prev. recved. a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhib., and a platinum-contain. chemother. in the neoadjuvant/adjuvant, locally adv. or metast. setting
• are ineligible for cisplatin-contain. chemother. and have prev. recved. one or more prior lines of ther.
C/I: Hypersens.
